Antithrombotics after Venous Stenting: Rather Different from Coronary Artery Stenting

Should the Antithrombotic/antiplatelet therapy following 10.0 by 60 mm stent implantation to the subclavian vein of a chronic kidney patient be the same as one following a 3.0 by 18 mm stent implantation to the second segment of the left anterior descending artery of this same patient? The daily practice of many interventional cardiologists performing<a href="https://solaci.org/en/2018/05/24/antithrombotics-after-venous-stenting-rather-different-from-coronary-artery-stenting/" title="Read more" >...</a>

Registro SCAAR a 10 años: el FFR mejora la toma de decisiones a muy largo plazo

EuroPCR 2018 | SCAAR Registry at 10 years: FFR improves decision making in the long term

The SCAAR registry aimed at showing the differences in mortality at very long term when using functional assessment of coronary lesions (with FFR or iFR) in patients with chronic stable angina. The study compared 3460 patients assessed with FFR/iFR against 21221 patients undergoing PCI based on angiography, between January 2005 and March 2015. As<a href="https://solaci.org/en/2018/05/24/europcr-2018-scaar-registry-at-10-years-ffr-improves-decision-making-in-the-long-term/" title="Read more" >...</a>

Is TAVR Durable Beyond 5 Years?

Courtesy of Dr. Carlos Fava. The benefits derived from transcatheter aortic valve replacement (TAVR) are clear and self-evident, and its progressively better outcomes are due to better patient selection, greater operator experience, and the development of new valves that enhance procedural safety and complexity. However, the question of durability remains a major unresolved issue, particularly now<a href="https://solaci.org/en/2018/05/22/is-tavr-durable-beyond-5-years/" title="Read more" >...</a>

Elderly Patients with ACS: Clopidogrel or Reduced-Dose Prasugrel?

Elderly patients are at elevated risk of both ischemic and bleeding complications after an acute coronary syndrome (ACS), and display higher platelet reactivity under clopidogrel when compared to younger patients. A 5-mg dose of prasugrel would provide more predictable platelet inhibition than clopidogrel in elderly populations, without the risk of bleeding entailed by the full<a href="https://solaci.org/en/2018/04/17/elderly-patients-with-acs-clopidogrel-or-reduced-dose-prasugrel/" title="Read more" >...</a>

Peri-Procedural Infarction: More Frequent than and Not as Innocent as We Thought

Almost 30% of all patients experience some degree of myocardial injury after elective angioplasty, a statistic associated to an increase in cardiovascular events at 30 days and 1 year, according to this study recently published in Eur Heart J. The study only included consecutive patients who underwent elective angioplasty with a negative troponin level at admission. The<a href="https://solaci.org/en/2018/04/13/peri-procedural-infarction-more-frequent-than-and-not-as-innocent-as-we-thought-2/" title="Read more" >...</a>

Peri-Procedural Infarction: More Frequent than and Not as Innocent as We Thought

Almost 30% of all patients experience some degree of myocardial injury after elective angioplasty, a statistic associated to an increase in cardiovascular events at 30 days and 1 year, according to this study recently published in Eur Heart J. The study only included consecutive patients who underwent elective angioplasty with a negative troponin level at admission. The<a href="https://solaci.org/en/2018/04/13/peri-procedural-infarction-more-frequent-than-and-not-as-innocent-as-we-thought/" title="Read more" >...</a>

ACC 2018 | DEFINE-FLAIR Sub-Analysis: iFR More Comfortable, Faster, and Much Cheaper

Using instantaneous wave-free ratio (iFR) to guide decisions on revascularization of intermediate lesions is cheaper than using fractional flow reserve (FFR). Based on costs from the DEFINE-FLAIR trial, researchers estimate the difference to be almost USD 1000. This should not be seen as good news for any given technology (iFR, in this case), but for physiologic<a href="https://solaci.org/en/2018/04/05/acc-2018-define-flair-sub-analysis-ifr-more-comfortable-faster-and-much-cheaper/" title="Read more" >...</a>

ACC 2018 | COMBO: New Stent with Thin Struts and Pro-Healing Membrane

The new COMBO stent, comprised of thin struts plus a bioengineered layer of endothelial progenitor cells, is safe and effective at 1 year, according to this registry (the largest study on this device to date). This new stent could provide a better option for patients at high risk for bleeding who may not be able to<a href="https://solaci.org/en/2018/04/04/acc-2018-combo-new-stent-with-thin-struts-and-pro-healing-membrane/" title="Read more" >...</a>

Doble antiagregación: menos es más en añosos.

Dual Antiplatelet Therapy: Less Is More for Elderly Patients

A recent meta-analysis that will be published soon in JACC Intv offers evidence of benefit derived from short-term dual antiplatelet therapy for elderly patients. This is a patient group that has always been excluded from the major trials, while remaining one of the most challenging subgroups in which to balance bleeding and ischemic risks. The<a href="https://solaci.org/en/2018/03/27/dual-antiplatelet-therapy-less-is-more-for-elderly-patients/" title="Read more" >...</a>

THEMIS: eventos isquémicos y hemorrágicos en difícil equilibrio para el ticagrelor crónico

New Study Shows Ticagrelor + Aspirin Reduce Events Rate

Just when we were starting to understand how long dual antiplatelet therapy should be for our patients, JACC publishes this study where ticagrelor combined with aspirin significantly reduces relative and absolute events rate at long term, especially in patients with multivessel disease. The PEGASUS-TIMI 54 assessed the long-term benefits of two different doses of ticagrelor (60 mg or<a href="https://solaci.org/en/2018/03/21/new-study-shows-ticagrelor-aspirin-reduce-events-rate/" title="Read more" >...</a>

thrombosis